ORGANON ALERT: Bragar Eagel & Squire, P.C. is Investigating Organon & Co. on Behalf of Organon Stockholders and Encourages Investors to Contact the Firm

Core Insights - Organon & Co. reported mixed Q1 FY25 results, with a revenue decline of 7% year-over-year to $1.51 billion, primarily due to a 17% decline in Biosimilars and an 11% drop in Established Brands following the loss of Atozet exclusivity [2] - The company announced a significant dividend cut from $0.28 to $0.02, representing a decrease of over 92%, which led to a more than 28% drop in its stock price on the same day [2] Company Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Organon on behalf of its stockholders, focusing on possible violations of federal securities laws and other unlawful business practices [1]